Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GILD Stock Summary
In the News
7 Value Stocks to Buy at a 52-Week Low in March
When it comes to finding the best value stocks to buy, sometimes you have to go against the grain. That is, dive into stocks that have fallen out of favor with the market, to assess whether investor sentiment is on the money, or an overreaction.
Gilead Sciences Finally Starts Succeeding
Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones planned for 2024.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know
Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.
2 Top Dividend Stocks to Buy Hand Over Fist
AbbVie and Gilead Sciences haven't been recording excellent financial results lately. But both drugmakers have solid lineups and pipelines that should allow them to recover.
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that business told Reuters.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $75.94, moving +1.15% from the previous trading session.
Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)
Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)
39 Upcoming Dividend Increases Including 2 Dividend Kings
Thirty-nine companies, including Coca-Cola and Telephone and Data Systems, are raising their dividends.
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
In the most recent trading session, Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day.
GILD Financial details
GILD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 17.68 | 19.64 | 21.74 | 21.74 | 21.73 | |
Net income per share | 4.24 | 0.07 | 4.96 | 3.66 | 4.54 | |
Operating cash flow per share | 7.2 | 6.5 | 9.06 | 7.23 | 6.42 | |
Free cash flow per share | 6.55 | 5.98 | 8.6 | 6.65 | 5.95 | |
Cash per share | 19.17 | 5.89 | 5.19 | 5.09 | 5.82 | |
Book value per share | 17.83 | 14.5 | 16.77 | 16.9 | 18.23 | |
Tangible book value per share | 3.74 | -18.31 | -16.5 | -12.75 | -9.63 | |
Share holders equity per share | 17.83 | 14.5 | 16.77 | 16.9 | 18.23 | |
Interest debt per share | 20.15 | 25.76 | 22.05 | 20.85 | 20.78 | |
Market cap | 82.52B | 73.23B | 91.2B | 107.74B | 101.1B | |
Enterprise value | 95.49B | 98.64B | 112.56B | 127.56B | 120B | |
P/E ratio | 15.32 | 822.84 | 14.65 | 23.46 | 17.85 | |
Price to sales ratio | 3.68 | 2.97 | 3.34 | 3.95 | 3.73 | |
POCF ratio | 9.03 | 8.97 | 8.01 | 11.88 | 12.63 | |
PFCF ratio | 9.92 | 9.74 | 8.44 | 12.91 | 13.62 | |
P/B Ratio | 3.64 | 4.02 | 4.33 | 5.08 | 4.44 | |
PTB ratio | 3.64 | 4.02 | 4.33 | 5.08 | 4.44 | |
EV to sales | 4.25 | 4 | 4.12 | 4.68 | 4.43 | |
Enterprise value over EBITDA | 15.51 | 11.59 | 11.9 | 12.27 | 10.26 | |
EV to operating cash flow | 10.44 | 12.08 | 9.89 | 14.06 | 14.99 | |
EV to free cash flow | 11.48 | 13.12 | 10.42 | 15.29 | 16.17 | |
Earnings yield | 0.07 | 0 | 0.07 | 0.04 | 0.06 | |
Free cash flow yield | 0.1 | 0.1 | 0.12 | 0.08 | 0.07 | |
Debt to equity | 1.09 | 1.72 | 1.27 | 1.19 | 1.1 | |
Debt to assets | 0.4 | 0.46 | 0.39 | 0.4 | 0.4 | |
Net debt to EBITDA | 2.11 | 2.99 | 2.26 | 1.91 | 1.62 | |
Current ratio | 3.23 | 1.39 | 1.3 | 1.36 | 1.46 | |
Interest coverage | 4.31 | 7.14 | 7.4 | 7.84 | 9.92 | |
Income quality | 1.7 | 91.78 | 1.84 | 1.99 | 1.43 | |
Dividend Yield | 0.04 | 0.05 | 0.04 | 0.03 | 0.04 | |
Payout ratio | 0.6 | 38.75 | 0.58 | 0.81 | 0.67 | |
Sales general and administrative to revenue | 0.16 | 0.18 | 0.17 | 0.18 | 0 | |
Research and developement to revenue | 0.41 | 0.2 | 0.2 | 0.18 | 0.21 | |
Intangibles to total assets | 0.29 | 0.6 | 0.61 | 0.59 | 0.56 | |
Capex to operating cash flow | -0.09 | -0.08 | -0.05 | -0.08 | -0.07 | |
Capex to revenue | -0.04 | -0.03 | -0.02 | -0.03 | -0.02 | |
Capex to depreciation | -0.59 | -0.44 | -0.28 | -0.35 | -0.22 | |
Stock based compensation to revenue | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | |
Graham number | 41.25 | 4.81 | 43.25 | 37.3 | 43.15 | |
ROIC | 0.09 | 0.01 | 0.11 | 0.12 | 0.16 | |
Return on tangible assets | 0.12 | 0 | 0.24 | 0.18 | 0.21 | |
Graham Net | -8.59 | -29.91 | -28.37 | -24.37 | -21.58 | |
Working capital | 21.73B | 4.42B | 3.45B | 3.99B | 5.17B | |
Tangible asset value | 4.75B | -23.01B | -20.72B | -16B | -12.02B | |
Net current asset value | -7.49B | -34.37B | -31.83B | -26.74B | -22.92B | |
Invested capital | 1.09 | 1.72 | 1.27 | 1.19 | 1.1 | |
Average receivables | 3.45B | 4.24B | 4.69B | 4.64B | 4.72B | |
Average payables | 751.5M | 778.5M | 774.5M | 805M | 727.5M | |
Average inventory | 1.44B | 2.54B | 2.87B | 2.78B | 3.09B | |
Days sales outstanding | 58.24 | 72.32 | 60.06 | 63.91 | 62.73 | |
Days payables outstanding | 55.67 | 67.38 | 38.98 | 58.39 | 33.64 | |
Days of inventory on hand | 161.38 | 240.62 | 151.18 | 181.95 | 205.86 | |
Receivables turnover | 6.27 | 5.05 | 6.08 | 5.71 | 5.82 | |
Payables turnover | 6.56 | 5.42 | 9.36 | 6.25 | 10.85 | |
Inventory turnover | 2.26 | 1.52 | 2.41 | 2.01 | 1.77 | |
ROE | 0.24 | 0 | 0.3 | 0.22 | 0.25 | |
Capex per share | -0.65 | -0.52 | -0.46 | -0.58 | -0.47 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.9 | 5.09 | 5.28 | 5.65 | 5.7 | |
Net income per share | 1.31 | 0.81 | 0.84 | 1.75 | 1.15 | |
Operating cash flow per share | 2.05 | 1.4 | 1.87 | 1.41 | 1.74 | |
Free cash flow per share | 1.9 | 1.31 | 1.76 | 1.31 | 1.57 | |
Cash per share | 5.1 | 4.71 | 10.97 | 5.5 | 5.82 | |
Book value per share | 16.94 | 16.78 | 16.89 | 17.82 | 18.23 | |
Tangible book value per share | -12.78 | -12.6 | -11.99 | -10.6 | -9.63 | |
Share holders equity per share | 16.94 | 16.78 | 16.89 | 17.82 | 18.23 | |
Interest debt per share | 20.33 | 21.43 | 21.48 | 20.94 | 20.22 | |
Market cap | 107.48B | 103.55B | 96.26B | 93.53B | 101.1B | |
Enterprise value | 127.3B | 125.13B | 117.16B | 113.73B | 120B | |
P/E ratio | 16.38 | 25.63 | 23.03 | 10.73 | 17.69 | |
Price to sales ratio | 14.55 | 16.3 | 14.59 | 13.27 | 14.21 | |
POCF ratio | 41.89 | 59.37 | 41.19 | 53.26 | 46.61 | |
PFCF ratio | 45.07 | 63.33 | 43.79 | 57.24 | 51.74 | |
P/B Ratio | 5.07 | 4.95 | 4.56 | 4.2 | 4.44 | |
PTB ratio | 5.07 | 4.95 | 4.56 | 4.2 | 4.44 | |
EV to sales | 17.23 | 19.7 | 17.75 | 16.13 | 16.87 | |
Enterprise value over EBITDA | 52.69 | 62.22 | 57.04 | 43.06 | 38.23 | |
EV to operating cash flow | 49.61 | 71.75 | 50.13 | 64.76 | 55.33 | |
EV to free cash flow | 53.38 | 76.53 | 53.3 | 69.6 | 61.41 | |
Earnings yield | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
Free cash flow yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Debt to equity | 1.19 | 1.27 | 1.26 | 1.16 | 1.1 | |
Debt to assets | 0.4 | 0.43 | 0.43 | 0.42 | 0.4 | |
Net debt to EBITDA | 8.2 | 10.73 | 10.17 | 7.65 | 6.02 | |
Current ratio | 1.36 | 1.37 | 1.1 | 1.34 | 1.46 | |
Interest coverage | 9.99 | 7.41 | 7.24 | 11.31 | 9.94 | |
Income quality | 1.57 | 1.77 | 2.25 | 0.81 | 1.53 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.56 | 0.96 | 0.9 | 0.44 | 0.66 | |
Sales general and administrative to revenue | 0.17 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.21 | 0.23 | 0.21 | 0.21 | 0.2 | |
Intangibles to total assets | 0.59 | 0.59 | 0.58 | 0.57 | 0.56 | |
Capex to operating cash flow | -0.07 | -0.06 | -0.06 | -0.07 | -0.1 | |
Capex to revenue | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | |
Capex to depreciation | -0.34 | -1.16 | -0.2 | -0.18 | -0.31 | |
Stock based compensation to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
Graham number | 22.34 | 17.48 | 17.83 | 26.47 | 21.67 | |
ROIC | 0.04 | 0.03 | 0.02 | 0.05 | 0.04 | |
Return on tangible assets | 0.06 | 0.04 | 0.04 | 0.08 | 0.05 | |
Graham Net | -24.43 | -24.39 | -18.24 | -22.49 | -21.58 | |
Working capital | 3.99B | 3.84B | 1.45B | 4.07B | 5.17B | |
Tangible asset value | -16B | -15.72B | -14.97B | -13.22B | -12.02B | |
Net current asset value | -26.74B | -26.57B | -25.83B | -24.12B | -22.92B | |
Invested capital | 1.19 | 1.27 | 1.26 | 1.16 | 1.1 | |
Average receivables | 4.57B | 4.47B | 4.2B | 4.51B | 4.73B | |
Average payables | 759.5M | 766M | 624.5M | 604M | 568M | |
Average inventory | 2.71B | 2.92B | 3.1B | 3.19B | 3.28B | |
Days sales outstanding | 58.19 | 58.97 | 57.68 | 61.15 | 58.95 | |
Days payables outstanding | 58.35 | 40.28 | 38.82 | 33.7 | 31.73 | |
Days of inventory on hand | 181.81 | 193.36 | 198.54 | 184.14 | 194.19 | |
Receivables turnover | 1.55 | 1.53 | 1.56 | 1.47 | 1.53 | |
Payables turnover | 1.54 | 2.23 | 2.32 | 2.67 | 2.84 | |
Inventory turnover | 0.5 | 0.47 | 0.45 | 0.49 | 0.46 | |
ROE | 0.08 | 0.05 | 0.05 | 0.1 | 0.06 | |
Capex per share | -0.14 | -0.09 | -0.11 | -0.1 | -0.17 |
GILD Frequently Asked Questions
What is Gilead Sciences, Inc. stock symbol ?
Gilead Sciences, Inc. is a US stock , located in Foster city of Ca and trading under the symbol GILD
Is Gilead Sciences, Inc. buy or a sell ?
30 stock analysts have 30 predictions with a medium analyst target price of $76.57. The lowest prediction is $54 and the highest is $112
What is GILD stock prediction ?
With a median analyst target price of $76, 1 stock analysts have made 1 forecasts in last 90 days. $76 is the lowest and $76 is the greatest projection.
What is Gilead Sciences, Inc. stock quote today ?
Gilead Sciences, Inc. stock price is $73.25 today.
Is Gilead Sciences, Inc. stock public?
Yes, Gilead Sciences, Inc. is a publicly traded company.